来宝网移动站

Covidien和GE医疗集团展开为期5年的合作

来宝网 2012/5/4点击2543次

 美国Covidien 通用(GE)医疗集团GE Healthcare Life Sciences

 

Covidien的检测技术融入GE医疗集团的患者监护系统,有助于提高临床决策

 

科罗拉多州博尔德和密尔沃基--(美国商业资讯)--Covidien (NYSE: COV)和GE医疗集团(NYSE: GE)今日宣布开展为期5年的全球合作,以将Covidien的检测技术融入GE医疗集团的监护仪。两家公司均是全球领先的医疗产品供应商,并且在患者监护及呼吸监护器材领域是公认的创新企业。

GE医疗集团监护解决方案总经理Matthias Weber指出:"GE医疗集团致力于向我们强大的监护技术提供广泛的参数测量,如GE自己的SpO2技术。凭借我们在设计关键医疗器械方面的百年历史,我们目前着重提供创新的临床检测技术。这种推进有可能有助于提升护理、质量以及患者安全。"

NellcorTM呼吸功能组合包括采用OxiMaxTM技术的Nellcor脉搏血氧测定和BISTM脑监护系统,该组合目前应用于多种GE医疗集团的监护仪。这包括CARESCAPETM监护仪B850和CARESCAPETM监护仪B650,它们结合了GE医疗集团在心脏和麻醉领域的强大传统优势。

与Covidien进行的合作体现了GE医疗集团致力于维持开放的监护构架,汇集患者数据流,并使之能为医疗点处的医生所用。例如,CARESCAPETM监护仪B850现可提供与Covidien检测的连接,并提供监护仪和医院信息系统之间的双向信息流,如电子病历以及无需单独监护仪即可进行的心电图测量。完整的临床资料可为医生提供有价值的信息,帮助指导他们进行决策,并提高诊疗及护理效率。

Covidien呼吸和监护解决方案总裁Robert J. White评论道:"将Covidien先进的参数组合与GE医疗集团的监护仪相结合,可在检测患者状况发生微妙但重要的变化方面为医生提供支持。通过提供患者生理状况的全面信息,可提高患者的安全并推进积极的疗效。"

 

此次合作充分利用 Covidien的患者监护技术组合,包括:

 

  • 采用OxiMax技术的Nellcor脉搏血氧测定,它是一个心搏动血氧测定平台,可在各种敏度水平以及困难条件下准确监护患者。Covidien的Nellcor脉搏血氧测定解决方案在单一的传感器设计中提供SpO2、脉率和呼吸速率。
  • INVOSTM/躯体血氧测定,它监护患者特定的血氧水平,以优化终末器官灌注,并有助于预防重要器官受损及神经损伤。
  • BIS脑监护,它检测麻醉药和镇静药对大脑的影响。

 

关于COVIDIEN

Covidien是一家全球领先的健康保健产品公司,致力于为改善患者的用药效果提供创新的医疗解决方案,并通过在临床领域的领导地位及卓越表现创造价值。Covidien在三大业务领域制造和销售业界领先的产品线,并提供相应服务,这三大领域是:医疗设备、医药产品和医疗用品。2011年,Covidien公司的营业收入高达116亿美元,公司在全球65个国家拥有41''000多名员工,其产品销往140多个国家。更多有关我们业务的信息,请访问公司网站:www.covidien.com。Nellcor、BIS、OxiMax和INVOS是Covidien在美国和其他国家的商标。

 

关于GE医疗集团

GE医疗集团提供变革性的医疗技术和服务,塑造患者护理新时代。我们在医疗成像与信息技术、医学诊断、病人监护系统、药物开发、生物制药生产技术、绩效提升以及绩效解决方案服务方面的广泛专业经验能够帮助客户以更低的成本,为全球更多患者提供更好的医疗保健。此外,我们还与医疗业领军者合作,力图促成全球政策的必要调整,实现向可持续发展的医疗体系的顺利转型。

我们着眼于全球,以降低成本、扩大可及范围、提高质量为重点,不断开发创新解决方案。在此过程中,我们的"健康创想"(healthymagination)远景蓝图计划邀请全世界加入我们的行列。GE医疗集团总部位于英国,是通用电气公司(纽约证券交易所:GE)旗下业务部门,年销售额达160亿美元。GE医疗集团员工全力为100多个国家的医护专业人员及患者服务。如需了解GE医疗集团的更多信息,请访问我们的网站:www.gehealthcare.com

 

请浏览我们的最新动态:http://newsroom.gehealthcare.com

 

免责声明:本公告之原文版本乃官方授权版本。译文仅供方便了解之用,烦请参照原文,原文版本乃唯一具法律效力之版本

 

联系方式:

 

GE医疗集团
Annette Busateri,262-442-0966
annette.busateri@ge.com

Covidien
Rhonda Luniak,303-406-8743
rhonda.luniak@covidien.com

 

Covidien and GE Healthcare Form Five-Year Collaboration

Bringing Covidien measurement technologies to GE Healthcare patient monitoring helps enhance clinical decision-making

BOULDER, Colo. & MILWAUKEE--(BUSINESS WIRE)--May. 3, 2012-- Covidien (NYSE: COV) and GE Healthcare(NYSE: GE), leading global providers of healthcare products and recognized innovators in patient monitoring and respiratory care devices, today announced a five-year, global collaboration to incorporate Covidien measurement technologies into GE Healthcare patient monitors.

“GE Healthcare is committed to making a broad range of parameter measurements available on our powerful monitoring technology, including GE’s own SpO2 technology,” said  Matthias Weber, General Manager, Monitoring Solutions at GE Healthcare. “Leveraging our 100-year history of designing life-critical devices, we are focused on delivering innovative clinical measurement technology. Such advances have the potential to support improved care, quality, and patient safety.”

The Nellcor™ Respiratory Function portfolio, which includes Nellcor pulse oximetry with OxiMax™ Technology, and the BIS™ Brain Monitoring system, are now available on many GE Healthcare patient monitors. This includes the CARESCAPE™ Monitor B850 and CARESCAPE™ Monitor B650, which combine GE Healthcare’s strong cardiac and anesthesiology heritage.

The Covidien collaboration reflects GE Healthcare’s commitment to maintain an open monitoring architecture, bringing together streams of patient data and making it usable for clinicians at the point of care. For instance, the CARESCAPE™ Monitor B850 now provides access to Covidien measurements, bi-directional information flows between the monitor and hospital information systems, such as electronic medical records, and electrocardiogram measurements without requiring a separate monitor. Integrated clinical information can provide valuable information for physicians, helping guide their decisions and enhance efficiency of care.

“The advanced parameter portfolio from Covidien, coupled with GE Healthcare’s patient monitors, supports clinicians in detecting subtle but critical variations in a patient’s status,” says  Robert J. White, President of Covidien Respiratory and Monitoring Solutions. “By delivering the full picture of a patient’s physiological status, patient safety and positive outcomes can be advanced.”

The collaboration leverages the Covidien portfolio of patient monitoring technologies, including:

  • Nellcor pulse oximetry with OxiMax Technology, a cardiac-based pulse oximetry platform, which accurately monitors patients at all acuity levels and in challenging conditions. The Nellcor pulse oximetry solution fromCovidien offers SpO2, Pulse Rate and Respiration Rate in a single sensor design.
  • INVOS™ Cerebral/Somatic Oximetry which monitors site-specific oxygen levels to optimize end-organ perfusion and help protect against devastating major organ morbidity and neurological injury.
  • BIS Brain Monitoring which measures the effects of anesthetics and sedatives on the brain.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals andMedical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business. Nellcor, BIS, OxiMax and INVOS are trademarks of Covidien in the U.S. and foreign countries.

ABOUT GE HEALTHCARE:

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com. CARESCAPE is a trademark of General Electric Company.

For our latest news, please visit http://newsroom.gehealthcare.com

 

Source: Covidien

GE Healthcare
Annette Busateri, 262-442-0966
annette.busateri@ge.com
or
Covidien
Rhonda Luniak, 303-406-8743
rhonda.luniak@covidien.com

推荐仪器
  • *
  • *
  • *
  • *